AR064425A1 - Composiciones farmaceuticas y metodo para el tratamiento de la inflamacion en el ganado y en otros animales - Google Patents
Composiciones farmaceuticas y metodo para el tratamiento de la inflamacion en el ganado y en otros animalesInfo
- Publication number
- AR064425A1 AR064425A1 ARP070105702A AR064425A1 AR 064425 A1 AR064425 A1 AR 064425A1 AR P070105702 A ARP070105702 A AR P070105702A AR 064425 A1 AR064425 A1 AR 064425A1
- Authority
- AR
- Argentina
- Prior art keywords
- saturated
- liquid preparation
- mixtures
- group
- penetration enhancer
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 206010061218 Inflammation Diseases 0.000 title 1
- 241001465754 Metazoa Species 0.000 title 1
- 230000004054 inflammatory process Effects 0.000 title 1
- 244000144972 livestock Species 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000002360 preparation method Methods 0.000 abstract 6
- 239000007788 liquid Substances 0.000 abstract 4
- 229920006395 saturated elastomer Polymers 0.000 abstract 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 abstract 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 abstract 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 abstract 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract 3
- 231100000223 dermal penetration Toxicity 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 239000003961 penetration enhancing agent Substances 0.000 abstract 3
- 239000002904 solvent Substances 0.000 abstract 3
- XMGQYMWWDOXHJM-JTQLQIEISA-N (+)-α-limonene Chemical compound CC(=C)[C@@H]1CCC(C)=CC1 XMGQYMWWDOXHJM-JTQLQIEISA-N 0.000 abstract 2
- 241000283690 Bos taurus Species 0.000 abstract 2
- NOOCSNJCXJYGPE-UHFFFAOYSA-N flunixin Chemical compound C1=CC=C(C(F)(F)F)C(C)=C1NC1=NC=CC=C1C(O)=O NOOCSNJCXJYGPE-UHFFFAOYSA-N 0.000 abstract 2
- 229960000588 flunixin Drugs 0.000 abstract 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 abstract 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 abstract 2
- 235000003441 saturated fatty acids Nutrition 0.000 abstract 2
- 150000004671 saturated fatty acids Chemical class 0.000 abstract 2
- 150000003505 terpenes Chemical class 0.000 abstract 2
- FQTLCLSUCSAZDY-UHFFFAOYSA-N (+) E(S) nerolidol Natural products CC(C)=CCCC(C)=CCCC(C)(O)C=C FQTLCLSUCSAZDY-UHFFFAOYSA-N 0.000 abstract 1
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 abstract 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 abstract 1
- 241000723346 Cinnamomum camphora Species 0.000 abstract 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 abstract 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 abstract 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 abstract 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 abstract 1
- FQTLCLSUCSAZDY-ATGUSINASA-N Nerolidol Chemical compound CC(C)=CCC\C(C)=C\CC[C@](C)(O)C=C FQTLCLSUCSAZDY-ATGUSINASA-N 0.000 abstract 1
- 229930008380 camphor Natural products 0.000 abstract 1
- 229960000846 camphor Drugs 0.000 abstract 1
- 229930007050 cineol Natural products 0.000 abstract 1
- 229960005233 cineole Drugs 0.000 abstract 1
- 150000005690 diesters Chemical class 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 150000002191 fatty alcohols Chemical class 0.000 abstract 1
- 229940074076 glycerol formal Drugs 0.000 abstract 1
- 150000002334 glycols Chemical class 0.000 abstract 1
- 230000004968 inflammatory condition Effects 0.000 abstract 1
- 229940041616 menthol Drugs 0.000 abstract 1
- WASNIKZYIWZQIP-AWEZNQCLSA-N nerolidol Natural products CC(=CCCC(=CCC[C@@H](O)C=C)C)C WASNIKZYIWZQIP-AWEZNQCLSA-N 0.000 abstract 1
- AALKGALVYCZETF-UHFFFAOYSA-N pentane-1,2,3-triol Chemical compound CCC(O)C(O)CO AALKGALVYCZETF-UHFFFAOYSA-N 0.000 abstract 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 abstract 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Ophthalmology & Optometry (AREA)
- Gynecology & Obstetrics (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87090706P | 2006-12-20 | 2006-12-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR064425A1 true AR064425A1 (es) | 2009-04-01 |
Family
ID=39262615
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070105702 AR064425A1 (es) | 2006-12-20 | 2007-12-18 | Composiciones farmaceuticas y metodo para el tratamiento de la inflamacion en el ganado y en otros animales |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US9006272B2 (enExample) |
| EP (1) | EP2120860B1 (enExample) |
| JP (1) | JP5377326B2 (enExample) |
| KR (1) | KR20090091328A (enExample) |
| CN (2) | CN101588789B (enExample) |
| AR (1) | AR064425A1 (enExample) |
| AU (1) | AU2007339312B2 (enExample) |
| BR (1) | BRPI0720500B1 (enExample) |
| CA (1) | CA2672964C (enExample) |
| CL (1) | CL2007003711A1 (enExample) |
| CO (1) | CO6190598A2 (enExample) |
| ES (1) | ES2714550T3 (enExample) |
| MX (1) | MX2009006893A (enExample) |
| NZ (1) | NZ598554A (enExample) |
| PE (1) | PE20081406A1 (enExample) |
| RU (1) | RU2466715C2 (enExample) |
| TW (1) | TWI350182B (enExample) |
| WO (1) | WO2008082507A2 (enExample) |
| ZA (1) | ZA200904329B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2738970A1 (en) * | 2008-10-31 | 2010-05-06 | Moberg Derma Ab | Topical composition comprising a combination of at least two penetration enhancing agents |
| EP2544662B1 (en) | 2010-03-10 | 2020-05-20 | Nuvo Pharmaceuticals Inc. | Foamable formulation |
| WO2012022837A1 (en) * | 2010-08-16 | 2012-02-23 | Helsingin Yliopisto | Transdermal compositions |
| JP5827954B2 (ja) * | 2010-09-30 | 2015-12-02 | 富山化学工業株式会社 | 経皮吸収製剤 |
| CA3186350A1 (en) * | 2013-02-27 | 2014-09-04 | Argenta Innovation Limited | Transdermal formulations |
| CN105769827B (zh) * | 2016-03-09 | 2018-07-17 | 金陵科技学院 | 用于动物清热镇痛氟尼辛葡甲胺涂膜剂及其制备方法 |
| KR20200065711A (ko) | 2018-11-30 | 2020-06-09 | 한원경 | 동물 피부질환 개선용 조성물 |
| BR112022000767A2 (pt) | 2019-07-16 | 2022-03-15 | Donaghys Ltd | Sistema de solvente transdérmico e métodos de uso |
| US11419876B2 (en) | 2019-09-06 | 2022-08-23 | Iowa State University Research Foundation, Inc. | Mirtazapine as a pre-shipping inhibitor of bovine respiratory disease |
| EP4251205A1 (en) * | 2020-11-25 | 2023-10-04 | Intervet International B.V. | Method of treatment of pain through buccal administration of flunixin |
| WO2022238965A1 (en) * | 2021-05-12 | 2022-11-17 | Argenta Innovation Limited | Veterinary transdermal formulation |
| CN114404360B (zh) * | 2021-12-16 | 2023-03-28 | 江西益昕葆生物科技有限公司 | 一种氟尼辛葡甲胺注射液的制备方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63225316A (ja) * | 1986-10-21 | 1988-09-20 | Nitto Electric Ind Co Ltd | 外皮投与用組成物 |
| JPH11222443A (ja) * | 1997-11-11 | 1999-08-17 | Saitama Daiichi Seiyaku Kk | 経皮吸収促進組成物および経皮吸収製剤 |
| CN100409847C (zh) * | 1999-11-19 | 2008-08-13 | 美国爱科赛尔制药有限公司 | 乌头属生物碱经皮给药系统 |
| JP4865958B2 (ja) * | 2001-05-23 | 2012-02-01 | 株式会社トクホン | 鎮痛抗炎症局所作用型の貼付剤 |
| US6790867B2 (en) * | 2002-05-20 | 2004-09-14 | Schering-Plough Animal Health Corporation | Compositions and method for treating infection in cattle and swine |
| WO2005009510A2 (en) * | 2003-07-23 | 2005-02-03 | The Regents Of The University Of California | Penetration enhancer combinations for transdermal delivery |
| KR100780983B1 (ko) * | 2003-07-31 | 2007-11-30 | 파마시아 앤드 업존 캄파니 엘엘씨 | 소염제의 분산성 제제 |
| DE10358525A1 (de) * | 2003-12-13 | 2005-07-07 | Bayer Healthcare Ag | Endoparasitizide Mittel zur topischen Applikation |
| US7618651B2 (en) * | 2004-06-24 | 2009-11-17 | Idexx Laboratories | Pharmaceutical compositions for drug delivery and methods of treating or preventing conditions using same |
| RU2006147288A (ru) * | 2004-07-19 | 2008-08-27 | Уорнер-Ламберт Компани Эл-Эл-Си (US) | Препарат для стимуляции роста волос |
| MX2007002961A (es) * | 2004-09-16 | 2008-03-13 | Bayer Healthcare Ag | Fromulaciones aplicables dermicamente para el tratamiento de enfermedades cutaneas en animales. |
| EP1954275A2 (en) | 2005-11-21 | 2008-08-13 | Schering-Plough Ltd. | Pharmaceutical compositions comprising buprenorphine |
-
2007
- 2007-12-14 PE PE2007001807A patent/PE20081406A1/es not_active Application Discontinuation
- 2007-12-18 CN CN2007800470359A patent/CN101588789B/zh active Active
- 2007-12-18 RU RU2009127500/15A patent/RU2466715C2/ru active
- 2007-12-18 JP JP2009542867A patent/JP5377326B2/ja active Active
- 2007-12-18 ES ES07867799T patent/ES2714550T3/es active Active
- 2007-12-18 AR ARP070105702 patent/AR064425A1/es not_active Application Discontinuation
- 2007-12-18 CN CN201310549264.8A patent/CN103690471B/zh active Active
- 2007-12-18 AU AU2007339312A patent/AU2007339312B2/en active Active
- 2007-12-18 NZ NZ59855407A patent/NZ598554A/xx unknown
- 2007-12-18 KR KR1020097014552A patent/KR20090091328A/ko not_active Ceased
- 2007-12-18 US US11/959,185 patent/US9006272B2/en active Active
- 2007-12-18 MX MX2009006893A patent/MX2009006893A/es active IP Right Grant
- 2007-12-18 EP EP07867799.4A patent/EP2120860B1/en active Active
- 2007-12-18 CA CA2672964A patent/CA2672964C/en active Active
- 2007-12-18 BR BRPI0720500A patent/BRPI0720500B1/pt active IP Right Grant
- 2007-12-18 WO PCT/US2007/025808 patent/WO2008082507A2/en not_active Ceased
- 2007-12-19 CL CL2007003711A patent/CL2007003711A1/es unknown
- 2007-12-19 TW TW096148778A patent/TWI350182B/zh not_active IP Right Cessation
-
2009
- 2009-06-17 CO CO09062884A patent/CO6190598A2/es not_active Application Discontinuation
- 2009-06-19 ZA ZA200904329A patent/ZA200904329B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20081406A1 (es) | 2008-10-17 |
| BRPI0720500A2 (pt) | 2014-02-04 |
| CA2672964A1 (en) | 2008-07-10 |
| JP5377326B2 (ja) | 2013-12-25 |
| CN101588789B (zh) | 2013-12-11 |
| EP2120860A2 (en) | 2009-11-25 |
| US20080153885A1 (en) | 2008-06-26 |
| WO2008082507A2 (en) | 2008-07-10 |
| CL2007003711A1 (es) | 2008-07-25 |
| TW200833367A (en) | 2008-08-16 |
| CN103690471A (zh) | 2014-04-02 |
| AU2007339312B2 (en) | 2013-06-06 |
| RU2466715C2 (ru) | 2012-11-20 |
| ES2714550T3 (es) | 2019-05-29 |
| CN103690471B (zh) | 2015-11-18 |
| CA2672964C (en) | 2018-04-03 |
| BRPI0720500A8 (pt) | 2015-12-29 |
| RU2009127500A (ru) | 2011-01-27 |
| KR20090091328A (ko) | 2009-08-27 |
| TWI350182B (en) | 2011-10-11 |
| WO2008082507A3 (en) | 2009-03-19 |
| NZ598554A (en) | 2013-08-30 |
| ZA200904329B (en) | 2010-05-26 |
| EP2120860B1 (en) | 2019-01-23 |
| CN101588789A (zh) | 2009-11-25 |
| JP2010513500A (ja) | 2010-04-30 |
| US9006272B2 (en) | 2015-04-14 |
| MX2009006893A (es) | 2009-07-03 |
| AU2007339312A1 (en) | 2008-07-10 |
| CO6190598A2 (es) | 2010-08-19 |
| BRPI0720500B1 (pt) | 2019-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR064425A1 (es) | Composiciones farmaceuticas y metodo para el tratamiento de la inflamacion en el ganado y en otros animales | |
| AR072223A1 (es) | Composiciones transdermicas farmaceuticas y metodo para tratar la inflamacion en el ganado vacuno | |
| ES2524320T3 (es) | Composición para la prevención o el tratamiento de enfermedad asociada con trombo o émbolo | |
| KR101689898B1 (ko) | 광선 각화증을 치료하기 위한 국소 조성물 | |
| JP2010513500A5 (enExample) | ||
| AR025434A1 (es) | Formulacion farmaceutica con contenido de derivados de benzamida, con solubilidad y absorcion oral mejoradas | |
| AR059575A1 (es) | Metodo para el tratamiento de enfermedades inflamatorias | |
| DK2121025T3 (en) | Methods and compositions for delivering a therapeutic agent | |
| CO2021011652A2 (es) | Ésteres de ácido graso como agentes anti-malassezia | |
| RU2017109903A (ru) | Композиции диклофенака натрия для местного применения | |
| RU2008114352A (ru) | Композиции для местного применения | |
| RU2016137349A (ru) | Успокоительный феромон для кошек | |
| Li et al. | Development of patch and spray formulations for enhancing topical delivery of sinomenine hydrochloride | |
| ES2617672T3 (es) | Composiciones antihelmínticas de bencimidazol | |
| AR110468A1 (es) | Formulaciones de buprenorfina de liberación sostenida y método de tratamiento | |
| AR048342A1 (es) | FORMAS DE DOSIFICACIoN FARMACÉUTICAS QUE COMPRENDEN EL ÁCIDO N-(2-(2-FTALIMIDOETOXI)-ACETIL)-L-ALANIL-D-GLUTÁMICO (LK-423) | |
| ES2333638B2 (es) | Uso del acido maslinico para el tratamiento de dolores de naturaleza nociceptiva, inflamatoria y neurogenica. | |
| AU2013200466A1 (en) | Compositions For The Treatment Of Actinic Keratosis | |
| JP2024514843A (ja) | 発作性疾患を治療するための医薬組成物及び方法 | |
| KR100880056B1 (ko) | 화상 치료용 제약 조성물 | |
| ES2932076T3 (es) | Moduladores agonistas de los receptores de glucocorticoides selectivos (SEGRAM) no esteroideos y usos de los mismos | |
| Qassim et al. | Local effect of intramuscular injection of meloxicam and diclofenac: an experimental, comparative and histological study | |
| WO2015016695A1 (es) | Novedoso sistema farmacéutico de entrega bifásica para el tratamiento del dolor y la inflamación | |
| WO2022112277A1 (en) | Method of treatment of pain through buccal administration of flunixin | |
| NL2016203B1 (nl) | Samenstelling en inrichting voor de behandeling van schimmelnagels. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |